(Q42950103)

11 November 2017

title

Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain (English)

1 reference

11 November 2017

Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules in Patients with Chronic Osteoarthritis Pain (English)

1 reference

DOI

10.3810/PGM.2010.07.2179

https://api.crossref.org/works/10.3810/PGM.2010.07.2179

14 June 2024

0 references

0 references

0 references

0 references

Nathaniel Katz

1

1 reference

11 November 2017

Martin Hale

series ordinal

2

1 reference

11 November 2017

David Morris

series ordinal

3

1 reference

11 November 2017

Joseph Stauffer

series ordinal

4

1 reference

11 November 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

full work available at URL

11 November 2017

http://www.tandfonline.com/doi/pdf/10.3810/pgm.2010.07.2179

1 reference

DOI

10.3810/PGM.2010.07.2179

https://api.crossref.org/works/10.3810/PGM.2010.07.2179

14 June 2024

published in

Postgraduate Medicine

1 reference

11 November 2017

volume

122

1 reference

11 November 2017

issue

4

1 reference

11 November 2017

page(s)

112-128

1 reference

Extended-release opioids for the management of chronic non-malignant pain

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Challenges in the development of prescription opioid abuse-deterrent formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Prevalence and characteristics of opioid use in the US adult population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

The use of opioids in the treatment of osteoarthritis: when, why, and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Enriched analgesic efficacy studies: an assessment by clinical trial simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

The Clinical Opiate Withdrawal Scale (COWS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Methodological issues in clinical trials of opioids for chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Nonspecific medication side effects and the nocebo phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

Two New Rating Scales for Opiate Withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2179

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.07.2179

1 reference

release_avhjrskukfes7fsqmy43fz3xsa

11 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/avhjrskukfes7fsqmy43fz3xsa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference